GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » Shiller PE Ratio

BioCardia (BioCardia) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 1996. Start your Free Trial

What is BioCardia Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCardia Shiller PE Ratio Historical Data

The historical data trend for BioCardia's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia Shiller PE Ratio Chart

BioCardia Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCardia Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCardia's Shiller PE Ratio

For the Biotechnology subindustry, BioCardia's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCardia's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCardia's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BioCardia's Shiller PE Ratio falls into.



BioCardia Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BioCardia's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, BioCardia's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.35/131.7762*131.7762
=-1.350

Current CPI (Mar. 2024) = 131.7762.

BioCardia Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.464 100.560 0.608
201409 0.302 100.428 0.396
201412 0.429 99.070 0.571
201503 0.535 99.621 0.708
201506 0.514 100.684 0.673
201509 0.584 100.392 0.767
201512 0.633 99.792 0.836
201603 0.577 100.470 0.757
201606 0.528 101.688 0.684
201609 32.400 101.861 41.915
201612 -55.188 101.863 -71.395
201703 -10.800 102.862 -13.836
201706 -10.800 103.349 -13.771
201709 -10.800 104.136 -13.667
201712 -12.450 104.011 -15.773
201803 -12.150 105.290 -15.206
201806 -11.400 106.317 -14.130
201809 -12.450 106.507 -15.404
201812 -12.750 105.998 -15.851
201903 -12.900 107.251 -15.850
201906 -11.550 108.070 -14.084
201909 -9.450 108.329 -11.495
201912 -7.200 108.420 -8.751
202003 -10.050 108.902 -12.161
202006 -6.900 108.767 -8.360
202009 -4.500 109.815 -5.400
202012 -2.250 109.897 -2.698
202103 -2.700 111.754 -3.184
202106 -3.000 114.631 -3.449
202109 -2.400 115.734 -2.733
202112 -3.150 117.630 -3.529
202203 -2.850 121.301 -3.096
202206 -2.100 125.017 -2.214
202209 -2.550 125.227 -2.683
202212 -2.400 125.222 -2.526
202303 -2.550 127.348 -2.639
202306 -2.550 128.729 -2.610
202309 -1.800 129.860 -1.827
202312 -1.350 129.419 -1.375
202403 -1.350 131.776 -1.350

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCardia  (NAS:BCDA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BioCardia Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BioCardia's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCardia (BioCardia) Business Description

Traded in Other Exchanges
Address
320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.
Executives
Frost Phillip Md Et Al 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau director C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo director C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Edward M Gillis officer: Senior Vice President, Devices C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Andrew Scott Blank director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen director C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer director C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman director, officer: President and CEO C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer 10 percent owner C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung officer: VP of Finance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Allan R Tessler director C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen officer: VP, Quality Assurance C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous director C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070

BioCardia (BioCardia) Headlines

From GuruFocus